Company intelligence / Profile preview

Pharmaleads

Paris, Île-de-France, Francepharmaleads.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 2

Overview

Pharmaleads develops non-opiate, small molecule drugs for the management of acute and chronic severe pain using its proprietary DENKI technology. The company’s approach leverages dual enkephalinase inhibitors to increase endogenous enkephalins for improved analgesia without opioid side effects. Its pipeline includes candidates targeting neuropathic, ocular, post-surgical pain, migraine disorders, and neuralgia. At least two products are in clinical or preclinical development; detailed recent clinical results are not specified in public sources.

Therapeutic areas: OphthalmologyNeurology
Modalities: Small molecules (specifically Dual ENKephalinase Inhibitors - DENKIs)
Industry: Biotech

Drug pipeline

2 assets

PL-265

Unknown

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Pharmaleads.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharmaleads.

Explore the full profile